Dean Schorno has joined 23andMe, a genetic information company with drug development aspirations, as its chief financial officer and head of operations. Schorno was previously at Seattle’s Adaptive Biotechnologies for a year and before that at Bay Area diagnostics company Genomic Health. Adaptive said last week that Chad Cohen would replace Schorno as CFO.
Author: Alex Lash
I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and Xconomy.
View all posts by Alex Lash
